Myeloperoxidase activity in individuals with Anti-neutrophil cytoplasmic antibodies (ANCA) can be inhibited by RLS-0071 At the 2021 Annual Conference of...
Read MoreNorfolk, VA, November 2, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer, will...
Read MoreNorfolk, VA, September 22, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer and...
Read MoreNorfolk, VA, September 22, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer and John...
Read MoreID Week – New Intestinal Necrosis Data Dr. Parvathi Kumar, ReAlta’s Associate Director of Early Clinical Development, will be presenting...
Read MoreRLS-0071 is in development for treatment of Acute Lung Injury (ALI) and Hypoxic Ischemic Encephalopathy (HIE) Norfolk, VA, June 8,...
Read MoreThe Virginian Pilot A Norfolk biotech startup researching treatments for a serious side effect of COVID-19 recently received another funding...
Read MoreRLS-0071 is in development for treatment of Acute Lung Injury (ALI) and Hypoxic Ischemic Encephalopathy (HIE) Norfolk, VA, May...
Read MoreProceeds to Fund Programs Addressing Acute Lung Injury (ALI) and Hypoxic Ischemic Encephalopathy (HIE) Norfolk, VA, April 28, 2021 —...
Read More